Clinical trial

AZD9291 US Expanded Access Program

NCT02451852

StatusNO_LONGER_AVAILABLE

Study typeEXPANDED_ACCESS

Start dateUnknown

PhaseN/A

Study timeline

Registry last updated2016-07-14

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

EGFR T790M Mutation Positive NSCLCunresolved

Interventions

AZD9291DRUG

Sponsors & collaborators

AstraZenecalead sponsor

Mapped research locations

New YorkNew York, United States1 BostonMassachusetts, United States1 ChicagoIllinois, United States1 DallasTexas, United States1 SeattleWashington, United States1 ColumbusOhio, United States1 DetroitMichigan, United States1 AustinTexas, United States1 RochesterMinnesota, United States1 CharlotteNorth Carolina, United States1 Winston-SalemNorth Carolina, United States1 BuffaloNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02451852 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.